Search

HarvardScience is a publication of the Harvard Office of News and Public Affairs devoted to all matters related to science at the various schools, departments, institutes, and hospitals of Harvard University.
Harvard Science medicine + health
After using a pair of enzymes to modify the structure of potent antibiotics in a test tube, a future step for Heather Losey and Christopher T. Walsh may be to see if they can manipulate bacteria to produce the redesigned drugs.

Photo by Graham Ramsay

Enzyme pair joins fight against drug-resistant bacteria

Researchers create new version of vancomycin

January 10, 2003

Scientists have been striving to develop antibiotics against drug-resistant bacterial strains. Most attempts have been plagued by a lack of molecular tools for manipulating -- and ultimately improving -- the structure of naturally occurring antibiotics. Harvard Medical School researchers Heather Losey, Christopher T. Walsh, and their colleagues reported in the Dec. 16, 2002 issue of the journal Chemistry & Biology that they harnessed two enzymes, which work by adding sugars to a central molecular core, and used them to create new versions of two potent antibiotics, vancomycin and teicoplanin. It is not clear if the new versions are effective against drug-resistant bacterial strains. "These drugs are not going to go on the market any time soon, but that was not our goal," said Losey, Harvard Medical School graduate student in biological chemistry and molecular pharmacology. "This is just the first step out of many to find out if we can tweak the molecules." What surprised Losey and Walsh, the Hamilton Kuhn professor of biological chemistry and molecular pharmacology, and their colleagues was how much tweaking they could do with the enzymes. "This just gives us more tools, more permutations to try," said Losey.

foundations environments animal, vegetable, + mineral medicine + health culture + society engineering + technology